ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

CCOP Applications Total 110(At Least), Plus 25 from Research Bases; All 57 Survivors Try Again

November 21, 1986

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

June 27, 2014

Letter to the Editor

February 21, 2003

Porter Novelli Gets $7.4M Contract For 5 A Day Program

October 4, 2002

Merritt To Head Nursing Center’s Implementation; Nurse Research And Training Opportunities Varied

January 10, 1986

ODAC Advice: Avoid ESAs In Curative Settings, Require Patients To Sign Informed Consent.

March 14, 2008